At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 676 enrolled
Drug / intervention
LEO 90105 = calcipotriol + betamethasone dipropionate +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy and Safety of LEO 90105 Ointment (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Japanese Subjects With Psoriasis Vulgaris
In Brief
A Phase 3 clinical trial evaluating LEO 90105 = calcipotriol + betamethasone dipropionate, Dovonex® = calcipotriol, and 1 other intervention for Psoriasis. Completed, enrolled 676 participants across 1 site.
Detailed Summary
The purpose of this study is to compare the efficacy of LEO 90105 ointment applied once daily with Dovonex® ointment applied twice daily and with Rinderon®-DP ointment applied once daily in Japanese subjects with psoriasis vulgaris.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
CountriesJapan
CollaboratorsQuintiles, Inc.
Timeline
Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartJul 2011
First PostedAug 2011
Primary CompletionApr 2012
TodayJul 2026
First PostedAug 24, 2011
Enrollment StartJul 1, 2011
Primary CompletionApr 1, 2012
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 14.9 years ago
Interventions
LEO 90105 = calcipotriol + betamethasone dipropionatedrug
Applied once daily for 4 weeks.
Dovonex® = calcipotrioldrug
Applied twice daily for 4 weeks.
Rinderon® - DP = betamethasone dipropionatedrug
Applied once daily for 4 weeks.